DBV Technologies SA Sponsored ADR

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Its peanut allergy patch tests quite well in very young patients.

Why DBV Technologies Was a Big Winner on Wednesday

HC Wainwright believes the most significant takeaway from DBV Technologies SA's (NASDAQ: DBVT) trial update was that 250ug treatment achieved the primary endpoint of difference between the percentage of treatment responders in the active compared to the placebo arm.

HC Wainwright Says Viaskin Benefit Affirmed In Toddlers...What's Next?

DBV Technologies SA's (NASDAQ: DBVT) pivotal Phase 3 EPITOPE trial of Viaskin Peanut 250 µg for peanut-allergic toddlers ages 1 to 3 years met its primary endpoint.  Viaskin Peanut demonstrated a statistically significant treatment effect, with 67.0% of subjects in the.

DBV Technologies Shares Jump On Positive Data From Peanut Allergy Trial In Toddlers

Broadway Financial

Energy Focus

Check these three penny stocks out for your watchlist The post Penny Stocks to Buy With Gains in After Hours? 3 to Watch  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks to Buy With Gains in After Hours? 3 to Watch

DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers

DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting

DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM)

Clarus Therapeutics Holdings

Transocean

Are these penny stocks on your watchlist right now? The post Hot Penny Stocks You Need to Know About This Month  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks You Need to Know About This Month

DBV Technologies S.A. (NASDAQ:DBVT ) Q1 2022 Results Conference Call May 2, 2022 5:00 PM ET Company Participants Anne Pollak - Head, IR Daniel Tassé - CEO Conference Call Participants Jon Wolleben - JMP Securities Operator Welcome to the DBV Technologies First Quarter 2022 Earnings Conference Call.

DBV Technologies S.A. (DBVT) CEO Daniel Tassé on Q1 2022 Results - Earnings Call Transcript

DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq

DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results

Montrouge, France, April 26, 2022 DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments

Correction: DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments

Montrouge, France, April 25, 2022 DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments

DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments

Montrouge, France, April 21, 2022 Ordinary and Extraordinary General Meeting of May 12 , 2022

Ordinary and Extraordinary General Meeting of May 12, 2022

Montrouge, France, March 14, 2022 DBV Technologies to Present at the Oppenheimer's 32nd Annual Healthcare Conference

DBV Technologies to Present at the Oppenheimer's 32nd Annual Healthcare Conference

DBV Technologies Announces Filing of 2021 Annual Report on Form 10-K and 2021 Universal Registration Document

DBV Technologies S.A. (DBVT) CEO Daniel Tassé on Q4 2021 Results - Earnings Call Transcript

DBV Technologies Reports Full Year 2021 Financial Results and Recent Business Updates

DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on March 3, 2022

DBV Technologies to Participate in Upcoming AAAAI 2022 Congress

DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conference

DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference

The road ahead for the peanut allergy treatment Viaskin Peanut is going to be rockier than investors had hoped.

Why DBV Technologies Stock Is Down Sharply on Tuesday

After reviewing the FDA's information requests and considering all other options, DBV Technologies (NASDAQ: DBVT) has decided not to pursue the sequential approach to develop Viaskin Peanut (allergen uptake/transport study before STAMP).  DBV estimates that heeding to the FDA's newly proposed sequential approach would require at least five rounds of exchanges requiring FDA alignment before initiating STAMP, a 6-month safety, and adhesion study.

DBV Technologies To Conduct New Pivotal Trial For Peanut Allergy Patch, Shares Plunge To 52-Week Low

DBV Technologies Provides Update on Investigational Viaskin™ Peanut

News for DBV Technologies SA Sponsored ADR Stock (DBVT)